Abstract Highlighting New Data from the Iomab-B Pivotal Phase 3 SIERRA Trial to be Presented at 2019 ASCO Annual Meeting May 16, 2019
Actinium Pharmaceuticals, Inc. Announces Pricing of $16.5 Million Public Offering of Common Stock and Warrants Apr 18, 2019
Actinium Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock and Warrants Apr 17, 2019
Actinium's Leading Clinical, Preclinical, Production and IP Efforts Related to Actinium-225 Highlighted at Preeminent Targeted Alpha Therapy International Symposium Apr 8, 2019
Actinium Highlights Actimab-A and Venetoclax Synergies Observed in New Studies Presented at AACR Apr 3, 2019
Actinium Successfully Completes Second Module of Collaborative Research Program with Astellas; Third Module Initiated Mar 29, 2019
Actinium Highlights its Participation at the Upcoming Targeted Alpha Therapy International Symposium with Presentations on its AWE Platform, Clinical Programs and New Source of Ac-225 Isotope Mar 26, 2019
Actinium Announces Update Including IP and New Data from Novel Combination of Actimab-A and Venetoclax Accepted for Poster Presentation at AACR Annual Meeting Mar 20, 2019
Actinium Appoints Accomplished FDA and Industry Professional Mamata Gokhale, Ph.D., RAC as Vice President, Global Head of Regulatory Affairs Mar 19, 2019
